Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ABAC Therapeutics

www.abactherapeutics.com

Latest From ABAC Therapeutics

REPAIR Is Trying To Fix The Antibiotic Gap Left By Industry

As large biopharmaceutical companies continue to exit antibacterial R&D, investments by Novo Holding’s REPAIR Impact Fund and grants from CARB-X can push forward novel therapies for drug-resistant microbial infections.

Infectious Diseases Financing

Venture Funding Deals: Celularity Launches With $250m; Generation Bio Grabs $100m Series B

Celularity launched with $250m to develop cell therapies with technology licensed from Celgene and others, while mRNA specialist Moderna brought in another $500m mega round and Generation Bio closed a $100m Series B to fund ongoing gene therapy programs.
Financing StartUps and SMEs

Novo $165m Superbug Fund is Fillip For Antibiotic Start-Ups

REPAIR will invest $20–40m per year over three–five years in 20 projects to combat antimicrobial resistance, with the hope that at least one of them will get to market.

Financing Infectious Diseases

ABAC Chief Calls For Better Antibiotic R&D Incentives In Europe

Fresh from raising €16m in a Series A round, Albert Palomer, CEO of Spain's ABAC Therapeutics, has outlined to Scrip the company's pathogen-specific approach to antibiotic research and his fears that biotechs in Europe are being held back by flaws in the continent's 'push' incentives schemes.

Infectious Diseases Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Spain
  • Parent & Subsidiaries
  • ABAC Therapeutics
  • Senior Management
  • Albert Palomer, CEO
    Domingo Gargallo-Viola, CSO
  • Contact Info
  • ABAC Therapeutics
    Phone: 93 230 11 54
    Joan XXIII, 10
    Barcelona, 08950
    Spain
Advertisement
Advertisement
UsernamePublicRestriction

Register